NCT04795245View on ClinicalTrials.gov

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

CompletedOBSERVATIONAL
Enrollment

805

Participants

Timeline

Start Date

August 26, 2021

Primary Completion Date

October 16, 2023

Study Completion Date

October 16, 2023

Conditions
Non-squamous, Non-Small Cell Lung Cancer
Interventions
DRUG

afatinib

afatinib

Trial Locations (1)

141-6017

Nippon Boehringer Ingelheim Co., Ltd., Tokyo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04795245 - Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma | Biotech Hunter | Biotech Hunter